tradingkey.logo

BioLife Solutions Inc

BLFS
View Detailed Chart
26.040USD
-0.250-0.95%
Close 11/11, 16:00ETQuotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM

BioLife Solutions Inc

26.040
-0.250-0.95%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.95%

5 Days

-3.95%

1 Month

-2.84%

6 Months

+11.81%

Year to Date

+0.31%

1 Year

-2.11%

View Detailed Chart

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

BioLife Solutions Inc's Score

Industry at a Glance

Industry Ranking
29 / 209
Overall Ranking
92 / 4608
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 10 analysts
Buy
Current Rating
32.100
Target Price
+22.10%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

BioLife Solutions Inc Highlights

StrengthsRisks
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Growing
The company is in a growing phase, with the latest annual income totaling USD 82.25M.
Undervalued
The company’s latest PE is -469.44, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 50.24M shares, decreasing 2.41% quarter-over-quarter.
Held by Chuck Royce
Star Investor Chuck Royce holds 521.80K shares of this stock.

BioLife Solutions Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

BioLife Solutions Inc Info

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
Ticker SymbolBLFS
CompanyBioLife Solutions Inc
CEOMr. Roderick De Greef
Websitehttps://www.biolifesolutions.com/
KeyAI